Psychedelics Revolution Creating a Multi-Billion-Dollar Opportunity

Following the Success of Compass Pathways, Numinus Wellness (NUMI.V)(LKYSF) Capitalizing on Potential $100 Billion Psychedelics Boom

Much like green leaf boom before it, psychedelics are quickly going mainstream.

News Update 12-11-20:
Numinus Wellness commends Health Canada for its intent to make MDMA and psilocybin treatment available through the Special Access Programme

And investors are jumping on board stocks in what could be a $100 billion market.3


With a market cap of $230 million, MindMed became the first publicly traded psychedelics stock on the market.4

Compass Pathways became the first to break into U.S. markets, and has become one of the most valuable psychedelic stocks on the market with a market cap of $1.29 billion.5

It also seems to be creating BIG opportunity for $22.95 million undervalued psychedelic company, Numinus Wellness (NUMI.V)(LKYSF), which just announced it began cultivating psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.

The Top 6 Reasons
to Consider Numinus Wellness
(NUMI.V)(LKYSF) Immediately

One, Numinus Wellness (NUMI.V)(LKYSF), which just announced it began cultivating psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.

Two, Numinus’ vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated.

Three, Numinus Wellness (NUMI.V)(LKYSF) is quickly getting caught up in a potential $100 billion market opportunity, as psychedelics gain momentum.

Four, the U.S. FDA and the medical community are supportive of psychedelics research. Plus, with the FDA being far more open-minded with psychedelic medicines, and with several major U.S. cities approving the decriminalization of psilocybin, the boom has only just begun.

Five, medical studies are finding that psychedelics can assist in the treatment of many health and mental issues impacting millions of people around the world.

Six, there’s rapidly changing consumer attitudes towards psychedelics, just as we saw with cannabis around the world.

The Psychedelics Opportunity is Out of this World, and Could Catapult Numinus Wellness

Again, much like the green leaf boom before it, psychedelics are quickly going mainstream.

Over the last few months, Denver, Oakland, and Santa Cruz have recently legalized its use. Joining them, Ann Arbor, Michigan lawmakers voted to decriminalize psilocybin mushrooms, as well. In addition, a ballot in Oregon could legalize its use by November 2020. 6

Even the Canadian government allowed four terminally ill patients with cancer to receive psilocybin therapy to help ease end-of-life distress. This is the first time in 46 years that an exemption has been given in Canada for patients to access such treatment.7

The best part — such drugs are already proving to be a major game changer for millions of people all over the world.

Countless studies are already proving such treatments can treat a host of mental issues, like:

Plus, with plenty of clinical trials supporting psychedelic treatments, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.

It’s part of the reason that Eight Capital estimates the total market for mental health treatment could be valued at up to $100 billion.8

The US FDA and the Medical Community Supports Psychedelics

With the FDA’s more open-minded approach to psychedelic medicines, and as several major U.S. cities continue to approve the decriminalization of psilocybin, for example, investors are speculating that the psychedelic boom could be sizable.

Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.9

Psychiatrists at Johns Hopkins even found that mushrooms can help with smoking cessation. Another Johns Hopkins’ study found psilocybin can help with alcohol dependence, too.10

A study in the journal, Nature — Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psilocybin treatments.11

“Our study demonstrates that psychedelics can produce beneficial behavioral effects without drastically altering perception, which is a critical step towards producing viable medicines inspired by these compounds,” said David Olson of UC Davis, as quoted by Esquire.

Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. The list of findings goes on and on.12

In fact, as the FDA and the medical community wake up to the opportunity, psychedelic growth could be out of this world, and revolutionize the way we treat a mental and health issues.

However, That’s Just a Fraction of the Numinus Wellness (NUMI.V)(LKYSF) Growth Story

Other recent developments include:

Numinus Health — Upgrades have commenced on the existing wellness clinic for compliance to the Multidisciplinary Association of Psychedelics Studies (MAPS) specifications for psychedelic-assisted psychotherapies, to ready the clinic for delivery of therapies and to provide a blueprint for the expansion of Numinus clinics in a range of jurisdictions in the future.

In addition, the Company claims to be fast-tracking plans for virtual delivery of transformative health solutions to counter COVID-related risks.

Numinus R&D — Refinements are being implemented in the Company’s clinical protocols to support MDMA and psilocybin research, and partnership discussions with leading research organizations are progressing, with the goal of making these substances accessible in a research context before they are widely available on the market.

Numinus Bioscience — The laboratory is preparing to add additional revenue streams as a contract analytical and research lab for psychedelic substances including MDMA, psilocybin, psilocin, DMT, and mescaline under its Health Canada Controlled Drugs and Substances licence.

“Numinus is setting the stage – and establishing its leadership position – for a future state where psychedelic-assisted psychotherapies are approved for clinical use outside of research,” says Payton Nyquvest, Founder, CEO, and Board Chair.

“We are progressing on our mission right now by creating the infrastructure and advancing evidence-based research to support routine clinical use in the health care system. We have the infrastructure, licenses, resources, and expertise to help hasten evidence-based accessibility to these treatments so we can, ultimately, help people heal and be well.”

Strong Leadership, Strong Results (NUMI.V)(LKYSF)

Successful companies tend to possess common traits, and one of those traits is a strong management team.  Numinus Wellness (NUMI.V)(LKYSF) (STOCK:NUMI) certainly has that ground covered.

Payton Nyquvest
Chairman and CEO

Former Director, VP and Head of Sales at Mackie Research Capital, one of Canada’s largest independent brokerage firms with a focus on public health and human advancement. Fifteen years’ experience in investment banking, has raised over $100 million for 100+ public and private companies. Former investment advisor with Jordan Capital Markets, Canaccord Financial.

Stacey Wallin
Chief Strategy Officer 

Former founder and CEO of LifeBooster, a tech startup now helping Fortune 100 clients detect and proactively respond to workplace injury risks. She most recently was the Director of Venture Programs at the BC Tech Association, leading the team developing accelerators for scale companies in BC with a mandate of solving the largest ecosystem and policy-related challenges facing growth and scale stage technology companies. Also founded and runs the Canadian Accelerator Incubator Network.

Dr. Evan Wood, MD, PhD
Chief Medical Officer

Recognized researcher with 20+ years of experience in addiction research, most recently as Executive Director of British Columbia Centre on Substance Use (BCCSU). Professor of Medicine at the University of British Columbia. Work on psychedelic-assisted psychotherapy includes involvement with the Multidisciplinary Association for Psychedelics Studies (MAPS) trial of MDMA-assisted psychotherapy and examining the potential of psilocybin assisted psychotherapy for a range of mental health disorders.

John Fong
Chief Financial Officer 

Experienced financial operator growing technology companies for the past five years, most recently as Managing Director of Invoke Digital. Prior to that, spent 15 years building international financial operations with companies listed on the TSX, NYSE, London AIM, and Lima Stock Exchange, the highlight of which was being on the founding team of Rio Alto Mining, a gold company that in three years went from exploration stage to generating net income of $100 million and operating cash flow of $98 million in its first year of commercial production.

Michael Tan
Chief Operating Officer

Former/first Executive Director, BCLDB Cannabis Division. Successfully launched recreational cannabis operations in BC. Twenty years’ operations management, strategic planning, and execution with national and multinational corporations including Hudson’s Bay, Saks Fifth Avenue, and UPS. Seasoned, high-impact operations, product development, and marketing executive with a track record of driving performance excellence and profitable revenue growth.

Dr. Devon Christie, MD, CCFP, IFMCP, RTC
Medical Director and Member of Clinical Advisory Council

Family physician with a focused practice in Multidisciplinary Pain Management and Registered Therapeutic Counselor, emphasizing Relational Somatic Therapy for trauma resolution. Teacher in the Certificate in Psychedelic-Assisted Therapies and Research post-graduate program at the California Institute of Integral Studies (CIIS). Trained to deliver MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy. Certified in Functional Medicine, Mindfulness-Based Street Reduction, Interpersonal Mindfulness, and Kundalini Yoga. Recognized speaker and expert on the potential of incorporating psychedelic-assisted therapies in an integrated healthcare model.

Judy Varga, M.Sc.
Head of Laboratory Operations

Analytical chemist with experience in the pharmaceutical industry. Previously GMP/GLP, QC lead with major Canadian LP for two years. Expertise in advanced microbiology methods.

Dr. Bernd O. Keller, PhD
Senior Research Scientist

Over 20 years of experience in advanced analytical technologies and methods. Authored 30 peer reviewed publications. Former research scientist of Child & Family Research Institute, BC Children’s Hospital. Former director of mass spectrometry facility at Queen’s University.

Dr. Kristina Grotzingrer, PhD, B.Sc.
Senior Research Scientist

Twenty years of phytochemistry experience in regulated lab environments. Health Canada-certified Qualified Person in Charge (QPIC). SR&ED projects (2013-present) in analytical methods for cannabis testing. Avid researcher and lecturer in health/herbal medicines and author of peer-reviewed research papers.

Kraig Docherty
Chief People Officer 

Twenty years of experience in strategic HR, operations, and talent positions, scaling high-growth companies including Electronic Arts, Activision Blizzard, Indochino, Invoke, and Eventbase. Recruited and hired over 1000 professionals around the world. Experience spanning human resources, culture building, recruiting and talent acquisition, employment branding, office design and construction, and community building.

Dr. Gabor Mate, M.D., C.M.
Author and Retired Physician

Dr. Maté is internationally recognised for his expertise in addiction, trauma, childhood development, and the link between stress and illness. Beyond his work as a medical practitioner, he is a sought-after speaker and bestselling author with reprints in over 25 languages. His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing, he has been awarded the Order of Canada, Canada’s highest civilian distinction, and the Civic Merit Award from his hometown of Vancouver, B.C.

As part of his effort to broaden public awareness of mental illness and contribute to the local community, Dr. Maté spent over a decade working in Vancouver’s Downtown Eastside caring for patients facing severe addiction and mental health challenges. Dr. Maté continues to push boundaries and identify new pathways for healing and advancement in mental health.

Dr. Pam Kryskow, MD, CCFP
Physician and Clinical Instructor, University of British Columbia

Practices medicine in British Columbia. Training includes Family Medicine, rural emergency medicine, chronic pain management, Functional Medicine, and ketamine assisted psychotherapy. Clinical instructor in the Department of Medicine at the University of British Columbia. Currently working with other university experts on research related to COVID-19, Ketamine Assisted Psychotherapy, Psychedelic Microdosing, MDMA for Chronic Pain, Psilocybin, and Psychedelic therapy.

Actively involved with colleagues bringing scientific education around psychedelic medicines to the forefront. She is working towards the goal for the safe use of psychedelic medicine for mental health and chronic pain improvement.

Zach Walsh, PhD
Associate Professor, Psychology, UBC

Clinical psychologist, Research Affiliate with the BC Centre on Substance Use. As Associate Professor of Psychology at the University of British Columbia, directs the Therapeutic, Recreational, and Problematic Substance Use lab. Published and presented widely on topics related to psychedelics, cannabis, mental health, and psychotherapy. Investigator for several ongoing studies of the therapeutic use of psychedelics and has worked clinically on trials of psychedelic-assisted psychotherapy.

Kate Browning
Administrator & Instructor, Holistic Health, Langara College

Registered Nurse specialized in mental health and substance use, psychotherapist, somatic therapist specialized in trauma and attachment, educator, and doctoral candidate in clinical psychology.  Former licensed and registered midwife with extensive training in subtle energy and consciousness-based healing practices. Worked in a variety of health care and educational settings for over 25 years as a clinician, clinical supervisor, consultant, educator, and lecturer. Currently an administrator and instructor in Continuing Studies with Langara College’s Holistic Health division. Trained in ketamine-assisted psychotherapy at the Orenda Institute and with the Center for Transformational Psychotherapy. Founding and board member of the Canadian Psychedelic Association.

Dr. Jason Marr, BScH, COC, ND
Founder & Director of Evoke Integrative Medicine Ltd.

Naturopathic doctor, performance and productivity coach, and an expert health and wellness speaker. Arms professionals and corporate leadership teams with the tools to maximize performance, productivity, and resilience. Employs an evidence-informed, holistic, and integrative approach.

The Top 6 Reasons
to Consider Numinus Wellness (NUMI.V)(LKYSF) Immediately

One, Numinus Wellness (NUMI.V)(LKYSF), which just announced it began cultivating psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.

Two, Numinus’ vertically integrated ecosystem positions the Company to be a first-in-market, trusted leader in the delivery of psychedelic-assisted psychotherapies when regulated.

Three, Numinus Wellness (NUMI.V)(LKYSF) is quickly getting caught up in a potential $100 billion market opportunity, as psychedelics gain momentum.

Four, the U.S. FDA and the medical community are supportive of psychedelics research. Plus, with the FDA being far more open-minded with psychedelic medicines, and with several major U.S. cities approving the decriminalization of psilocybin, the boom has only just begun.

Five, medical studies are finding that psychedelics can assist in the treatment of many health and mental issues impacting millions of people around the world.

Six, there’s rapidly changing consumer attitudes towards psychedelics, just as we saw with cannabis around the world.

 

Source 1: https://www.livescience.com/psilocybin-depression-breakthrough-therapy.htmlSource 2: https://www.hopkinsmedicine.org/news/newsroom/news-releases/johns-hopkins-launches-center-for-psychedelic-research

Source 3: https://money.usnews.com/investing/articles/why-investing-in-psychedelic-medicine-could-be-better-than-cannabis

Source 4: https://www.thecannabisinvestor.ca/mindmed-becomes-first-psychedelics-firm-to-go-public-following-historic-ipo/

Source 5: https://www.fool.com/investing/2020/09/21/why-compass-pathways-is-soaring-today/

Source 6: https://www.opb.org/news/article/psychedelic-mushrooms-psilocybin-measure-approved-oregon-november-ballot/

Source 7: https://www.cnn.com/2020/08/06/world/canada-psychedelic-mushrooms-cancer-therapy-trnd/index.html

Source 8: https://www.businessinsider.com/eight-capital-analyst-mindmed-psychedelics-industry-ammar-shah-2020-5

Source 9: https://www.hopkinsmedicine.org/news/newsroom/news-releases/johns-hopkins-launches-center-for-psychedelic-research

Source 10: https://www.hopkinsmedicine.org/news/stories/mushrooms_quit_smoking.html

Source 11: https://www.nature.com/articles/s41598-017-13282-7

Source 12: https://financialpost.com/cannabis/cannabis-business/first-pot-then-magic-mushrooms-decriminalization-is-spreading

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This website/newsletter is owned, operated and edited by TD Media  LLC.  Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC.  This webpage/newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies.  By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies.

To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only.  We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices.  Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 11/30/20 and ending on 12/25/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid fifty thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/26/20 and ending on 01/26/21 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid one hundred twenty five thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/21/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional fifty thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid one hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).

Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 12/14/20 and ending on 12/28/20 to publicly disseminate information about (NUMI) via digital communications. We have been paid an additional one hundred thousand USD via bank wire transfer. We own zero shares of (NUMI). To date we have been paid two hundred seventy five thousand USD via bank wire transfer. We own zero shares of (NUMI).

Disclaimer

Privacy Policy